Preclinical studies have established that implantation of bone marrow-mononuclear cells, including endothelial progenitor cells, into ischaemic limbs increases collateral vessel formation. We investigated efficacy and safety of autologous implantation of bone marrow-mononuclear cells in patients with ischaemic limbs because of peripheral arterial disease.
We first did a pilot study, in which 25 patients (group A) with unilateral ischaemia of the leg were injected with bone marrow-mononuclear cells into the gastrocnemius of the ischaemic limb and with saline into the less ischaemic limb.
Background Rheumatoid arthritis (RA) is a autoimmune disease,which is characterized by the osteoclasia or the high deformity rate of cartilage and bone. According to some materials, Mesenchymal stem cells (MSCs) were definited as the cell full of proliferation, differentiation capacity, and potential immune regulation. MSCs transplantation could be a appropriate-designed pattern to the joint damaging from rheumatoid arthritis (RA).However,
This study was undertaken to evaluate the efficacy of intramyocardial bone marrow cell (BMC) transplant therapy for ischemic heart disease (IHD).
The PubMed, Embase, and Cochrane Library databases through October 2013 were searched for randomized clinical trials (RCTs) of intramyocardial BMCs to treat IHD. The primary endpoint was change in left ventricular ejection fraction (LVEF).
Raynaud phenomenon is chronic vasospasm of the fingers, ears, nose and toes that occurs in response to stress or cold exposure, with a prevalence rates of 11% in women and 8% in men according with EEUU statistics. Secondary Raynaud phenomenon is associated with another disease like autoimmune disease. In our clinical center since 2010, 22 patients with secondary severe Raynaud syndrome (Lupus,
Mesenchymal stem cells (MSCs) are multipotent cells with the capacity to undergo chondrogenic differentiation. Systemically administered MSCs have been shown to preferentially accumulate at sites of tissue damage and inflammation, thus MSC-based therapy holds great promise for the treatment of inflammatory diseases such as RA. Modulation of MSC homing may allow targeted delivery of systemically administered MSCs to damaged articular cartilage,
In patients with osteoarthritis (OA), bone marrow lesions (BMLs) are intimately linked to disease progression. We hypothesized that aberrant multipotential stromal cell (also known as mesenchymal stem cell [MSC]) responses within bone tissue contributes to BML pathophysiology. The aim of this study was to investigate BML and non-BML native subchondral bone MSCs for numeric, topographic,
Rheumatoid arthritis (RA) is char – acterised with chronic inflammatory synovitis and progressive joint. Be – cause damaged and/or deformed joints cannot be repaired, a novel treatment strategy aimed at both anti-inflamma – tion and bone regeneration is a prereq – uisite. Mesenchymal stem cells (MSCs) can be easily isolated from various or – gans and possess multipotent capacity and exhibit immunoregulatory proper –
This study evaluated the effect of bone marrow-derived stem cells (BMSCs) on degenerative changes of TMJ associated with bovine collagen type II (BCII) induced-arthritis.
Materials and Methods
Fifty rabbits were divided into 3 groups. Group I (n = 10) received no treatment. Group II (n = 20) was divided into 2 subgroups according to treatment type.
Background: A cell combination of human mesenchymal stem cells (MSCs) and c-kit+ cardiac stem cells (CSCs) improves left ventricular (LV) performance to a greater degree than MSCs alone in post myocardial infarction swine. To advance the development of cell combination therapy, we administered autologous swine cells, and tested the hypothesis that transendocardial autologous CSCs/MSCs produces greater improvement of performance than MSCs in a rigorous model of heart failure due to post infarct LV remodeling.
The objective of this paper is to analyze the role of bone marrow-derived mesenchymal stem cells (BM-MSCs) on the differentiation of T follicular helper (Tfh) cells in lupus-prone mice.
Bone marrow cells were isolated from C57BL/6 (B6) mice and cultured in vitro, and surface markers were identified by flow cytometry. Naïve CD4+ T cells,